Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 868,626
  • Shares Outstanding, K 66,358
  • Annual Sales, $ 0 K
  • Annual Income, $ -180,310 K
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.84
  • Number of Estimates 3
  • High Estimate -0.70
  • Low Estimate -0.91
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -13.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.37 +15.13%
on 06/12/20
13.64 -4.03%
on 07/06/20
+0.70 (+5.69%)
since 06/10/20
3-Month
10.71 +22.22%
on 04/15/20
16.79 -22.04%
on 05/12/20
+1.60 (+13.93%)
since 04/09/20
52-Week
7.52 +74.07%
on 03/18/20
27.15 -51.79%
on 12/12/19
-7.87 (-37.55%)
since 07/10/19

Most Recent Stories

More News
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic...

ARPO : 1.2600 (-4.55%)
GOSS : 13.09 (unch)
Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19

Aerpio Pharmaceuticals, Inc. (the "Company") (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations...

ARPO : 1.2600 (-4.55%)
GOSS : 13.09 (unch)
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma

Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced...

ARPO : 1.2600 (-4.55%)
GOSS : 13.09 (unch)
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - June 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that...

NVS : 87.01 (-0.38%)
GOSS : 13.09 (unch)
GOSS FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020

New York, New York--(Newsfile Corp. - June 2, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc.("Gossamer " or "the Company")...

NVS : 87.01 (-0.38%)
GOSS : 13.09 (unch)
Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Gossamer Bio, Inc. to Contact the Firm

New York, New York--(Newsfile Corp. - June 2, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company")...

NVS : 87.01 (-0.38%)
GOSS : 13.09 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS

New York, New York--(Newsfile Corp. - June 2, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:

NVS : 87.01 (-0.38%)
GOSS : 13.09 (unch)
LAWSUITS FILED AGAINST GOSS, LBRT and FITB - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / June 2, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased...

GOSS : 13.09 (unch)
LBRT : 5.36 (+2.68%)
FITB : 18.39 (+5.75%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, SERV and BBBY

NEW YORK, NY / ACCESSWIRE / June 2, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

GOSS : 13.09 (unch)
SERV : 36.40 (+1.59%)
BBBY : 8.19 (+4.26%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, GSX and BIDU

NEW YORK, NY / ACCESSWIRE / June 2, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

GOSS : 13.09 (unch)
GSX : 87.63 (-0.26%)
BIDU : 132.33 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GOSS with:

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

2nd Resistance Point 13.71
1st Resistance Point 13.40
Last Price 13.09
1st Support Level 12.84
2nd Support Level 12.59

See More

52-Week High 27.15
Fibonacci 61.8% 19.65
Fibonacci 50% 17.33
Fibonacci 38.2% 15.02
Last Price 13.09
52-Week Low 7.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar